375853-98-8

Basic information

• Product Name: tert-butyl 1-(3-broMophenyl)ethylcarbaMate
• Synonyms: tert-butyl 1-(3-broMophenyl)ethylcarbaMate;CarbaMic acid, [1-(3-broMophenyl)ethyl]-, 1,1-diMethylethyl ester;[1-(3-Bromo-phenyl)-ethyl]-carbamic acid tert-butyl ester;N-BOC-1-(3-bromophenyl)ethanamine
• CAS NO: 375853-98-8
• Molecular Formula: C₁₃H₁₈BrNO₂
• Molecular Weight: 300.19152
• EINECS: -0
• Mol File: 375853-98-8.mol

Chemical Properties

• Boiling Point: 375.5±25.0 °C(Predicted)
• Appearance: /
• Density: 1.282±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 12.02±0.46(Predicted)
• CAS DataBase Reference: tert-butyl 1-(3-broMophenyl)ethylcarbaMate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 1-(3-broMophenyl)ethylcarbaMate(375853-98-8)
• EPA Substance Registry System: tert-butyl 1-(3-broMophenyl)ethylcarbaMate(375853-98-8)

Safety Data

• Hazardous Substances Data: 375853-98-8(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
Tert-butyl 1-(3-bromophenyl)ethylcarbamate is used as an intermediate in the synthesis of various organic compounds. Its carbamate group and tert-butyl group provide unique reactivity and stability, making it a valuable component in the preparation of pharmaceuticals and other biologically active molecules.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, tert-butyl 1-(3-bromophenyl)ethylcarbamate is used as a building block for the development of new drugs. Its structural features allow for the creation of molecules with specific biological activities, contributing to the advancement of medicinal chemistry.
Used in Biologically Active Compounds:
Tert-butyl 1-(3-bromophenyl)ethylcarbamate is also utilized in the synthesis of biologically active compounds, such as agrochemicals and other bioactive molecules. Its versatility in chemical reactions enables the production of a wide range of compounds with potential applications in various fields.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 74877-08-0 1-(3-bromophenyl)ethanamine 
• 24280-05-5 N-[1-(3-bromophenyl)ethylidene]hydroxyl amine 
• 2142-63-4 1-(3-Bromophenyl)ethanone 

Downstream Products

• 887254-63-9 (R,S)-tert-butyl 1-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethylcarbamate 
• 1027256-76-3 methyl 3-{1-[(tert-butoxycarbonyl)amino]ethyl}benzoate 
• 1439400-36-8 C₁₉H₂₉NO₄ 
• 1439400-38-0 C₁₅H₂₁NO₄ 
• 1439398-07-8 C₃₃H₃₉N₇O₄S 
• 1439398-42-1 C₂₈H₃₁N₇O₂S 

Relevant articles and documents

HETEROCYCLIC INHIBITORS OF GLUTAMINASE

The invention relates to the heterocyclic compounds of Formula (I) as defined further herein, and pharmaceutical preparations thereof. The invention further relates to methods of treating cancer, immunological or neurological diseases using the heterocyclic compounds of the invention.

INHIBITORS OF KINASE ACTIVITY

The present invention relates to pyridines or pyrazines that inhibit kinases. In particular the compounds of the invention inhibit members of the class III PTK receptor family such as FMS (CSF-IR), c-KIT, PDGFRβ, PDGFRα or FLT3 and KDR, SRC, EphA2, EphA3, EphA8, FLTl, FLT4, HCK, LCK, PTK5 (FRK), SYK, DDRl and DDR2 and RET. The compounds of the invention are useful in the treatment of kinase associated diseases such as immunological and inflammatory diseases; hyperproliferative diseases including cancer and diseases involving neo-angiogenesis; renal and kidney diseases; bone remodeling diseases; metabolic diseases; and vascular diseases.

Imidazo-fused oxazolo[4,5-b]pyridine and imidazo-fused thiazolo[4,5-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same

The present invention provides for pyrazolopurine-based tricyclic compounds having the formula (I), wherein R1, R2, R3, and R6 are as described herein. The present invention further provides pharmaceutical compositions comprising such compounds, as well as the use of such compounds for treating inflammatory and immune diseases.

Chemical compounds

Provided herein are novel and useful compounds having a tryptase inhibition activity, pharmaceutical compositions comprising such compounds, and methods treating subjects suffering from a condition, disease, or disorder that can be ameliorated by the administration of an inhibitor of tryptase, e.g., asthma and inflammatory diseases, to name only a few.